Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Research

SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022

Lauren E. Bloomfield, Sera Ngeh, Gemma Cadby, Kate Hutcheon, and Paul V. EfflerComments to Author 
Author affiliations: The University of Notre Dame Australia, Fremantle, Western Australia, Australia (L.E. Bloomfield); Western Australia Department of Health, East Perth, Western Australia, Australia (L.E. Bloomfield, S. Ngeh, G. Cadby, K. Hutcheon, P.V. Effler)

Main Article

Table 5

Vaccine effectiveness against severe COVID-19, 2 or 3 doses versus unvaccinated, Western Australia, Australia, February 1, 2022–May 31, 2022*

Vaccination status Case-patients, hospital admission or death
Controls
Vaccine effectiveness, % (95% CI)†
Vaccinated Unvaccinated Vaccinated Unvaccinated
Two doses 131 69 148 52 41.9 (4.8–64.5)
Three doses 795 259 982 72 81.7 (73.9–87.2)

*Severe disease was defined as hospitalization for SARS-CoV-2 infection with 7 d of positive SARS-CoV-2 PCR results and/or death from any cause. †Vaccine effectiveness calculated with conditional logistic regression by using case–control pairs matched by week of testing, age group, sex, Aboriginality, Index of Relative Socioeconomic Advantage and Disadvantage, and comorbidity score.

Main Article

Page created: April 19, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external